Latest Pathology News

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

Sonic Healthcare announces a major leadership transition with Dr Colin Goldschmidt retiring after 32 years as CEO, succeeded by Dr Jim Newcombe. The company also appoints Evangelos Kotsopoulos as Chief Operating Officer to support its global growth ambitions.

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.